Trilink was Maravai Lifesciences Holdings’s largest segment in fiscal 2025, bringing in $119.79M of $185.74M (64%).
| Segment | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Nucleic Acid Production | $813.08M | — | — | — | |||
| Trilink | — | $224.77M | $196.35M | $119.79M | |||
| Cygnus | — | $64.18M | $62.84M | $65.96M | |||
| Biologics Safety Testing | $69.93M | — | — | — | |||
| Protein Detection | — | — | — | — | |||
| Intersegment Revenues | -$7.00K | -$3.00K | — | — | |||
| Intersegment Eliminations | — | — | — | — | |||
| Total | $883.00M | $288.95M | $259.19M | $185.74M |
Maravai Lifesciences Holdings brought in $185.74M from its two segments in fiscal 2025, the year ended December 31, 2025. That was down 28.3% from $259.19M in fiscal 2024. Trilink was the largest at $119.79M (64.5%), ahead of Cygnus at $65.96M (35.5%).
Compared with fiscal 2024, Cygnus grew 5.0% to $65.96M, while Trilink fell 39.0% to $119.79M.
Maravai Lifesciences Holdings began breaking out Trilink in fiscal 2023 and Cygnus in fiscal 2023. Maravai Lifesciences Holdings stopped reporting Nucleic Acid Production ($813.08M in fiscal 2022) and Biologics Safety Testing ($69.93M in fiscal 2022) as separate segments.
North America was Maravai Lifesciences Holdings’s largest region in fiscal 2025, bringing in $112.38M of $185.74M (61%).
| Geography | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| North America | $339.47M | $141.06M | $127.09M | $112.38M | |||
| Europe, The Middle East & Africa | $432.93M | $49.92M | $42.06M | $30.92M | |||
| Asia Pacific | $109.79M | $97.44M | $89.38M | $41.47M | |||
| Latin & Central America | $808.00K | $527.00K | $662.00K | $971.00K | |||
| Total | $883.00M | $288.95M | $259.19M | $185.74M |
Maravai Lifesciences Holdings brought in $185.74M from its four regions in fiscal 2025, the year ended December 31, 2025. That was down 28.3% from $259.19M in fiscal 2024. North America was the largest at $112.38M (60.5%), ahead of Asia Pacific at $41.47M (22.3%) and Europe, The Middle East & Africa at $30.92M (16.6%). The remaining region, Latin & Central America, brought in $971.00K.
Compared with fiscal 2024, every region above 2% of revenue shrank. North America held up best, down 11.6% to $112.38M, and Asia Pacific fell the most, down 53.6% to $41.47M. From fiscal 2022 to 2025, combined revenue from these regions fell from $883.00M to $185.74M, a compound annual decline of 40.5%. North America's share of the total rose from 38.4% to 60.5%.
Maravai Lifesciences Holdings (MRVI) reports its revenue by segment and by geography. In fiscal 2025, Trilink was its largest segment, bringing in $119.79M (64.5% of the total), followed by Cygnus at $65.96M (35.5%).
Trilink was Maravai Lifesciences Holdings' largest segment in fiscal 2025, bringing in $119.79M, or 64.5% of the $185.74M total across its two segments.
North America was Maravai Lifesciences Holdings' largest region in fiscal 2025, bringing in $112.38M, or 60.5% of the $185.74M total across its four regions.
Cygnus grew faster than Trilink in fiscal 2025, up 5.0% from $62.84M to $65.96M. Trilink fell 39.0% to $119.79M.
Every figure comes from Maravai Lifesciences Holdings' annual financial filings, as reported. Each line keeps the name Maravai Lifesciences Holdings gives it, and years follow its fiscal calendar.
Maravai Lifesciences Holdings' revenue by segment goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.